baber/WOPTO huggingface dataset:
Patent FI-904703-A0 (FI)
Inventor: HAODEN ERIK
IPC: A01L7/02
Filed: 1990-09-25
Abstract: This invention relates to a hoof-fitting or horseshoe, comprising a metallic part (10) which is intended to be affixed to the underside of the horse's hoof, and a resilient or elastic shock-absorbing member (13) which is removeably affixed to the metallic part (10). In accordance with the invention, the metallic part and the resilient member (10 and 13 respectively) are configured substantially identically from respective sheets of material, wherein the metallic part (10) has stationarily mounted therein nut-like devices (12), the ends of which projecting from the plane of the metallic part (10) project into holes (14) provided in the shock-absorbing member (13). The metallic part (10) and the resilient shock-absorbing member (13) are joined together detachably with the aid of screw means (15). <IMAGE>
Patent FI-906344-A0 (FI)
Inventor: NODA KAZUO
IPC: A61K9/28
Filed: 1990-12-21
Abstract: A controlled release pharmaceutical preparation comprising (a) a core containing a pharmaceutically active substance and an organic acid, and (b) a coating film formed on the surface of the core by aqueous coating of a water-insoluble and slightly water-permeable acrylic polymer containing a trimethylammonium-ethyl group, which exhibits well controlled dissolution and release of the pharmaceutically active substance when administered and can maintain the desired blood level of the active substance for a long period of time, and a method for producing the preparation.
Patent FI-914067-A0 (FI)
Inventor: KARHU RAIMO
IPC: D07B9/00
Filed: 1991-08-28
Abstract: The invention relates to a reverse stranding apparatus for the reverse stranding of conductors. The apparatus comprises a stationary divider means, a twisting means rotatable in different directions, and a central element (5) disposed between said parts, and peripheral tubes (6) surrounding said central element, the central element (5) and the peripheral tubes (6) being pressed against each other at least during the twisting step of the conductors and the conductors to be stranded being adapted to pass through at least the peripheral tubes. To attain high speeds of rotation, the peripheral tubes (6) and the central element (5) are united in a tube packet (4) by means of a reticular fabric (7) enveloping the peripheral tubes (6) and extending substantially over the entire length of said peripheral tubes. <IMAGE>
Patent FI-914116-A0 (FI)
Inventor: MEUL THOMAS
IPC: C07B57/00
Filed: 1991-09-02
Abstract: The enantiomers of 2,2-dimethylcyclopropanecarboxylic acid are separated by salt formation with optically active 1-(3-methoxyphenyl)-ethylamine, fractional crystallization of the diastereomeric salts and subsequent decomposition of the salts with a strong acid.
Patent FI-922370-A0 (FI)
Inventor: CZOMBA GYULA
IPC: B21C1/04
Filed: 1992-05-22
Abstract: Steel wire for reinforcing embedding materials, especially concrete, in which the outline (4) of the cross-section is a three-branched epitrochoid which also has gradually widening and disappearing ribbing (5) along three generatrices with a constant increase in thread pitch, the maximum depth of which corresponds to the difference between the radius (rk) of the circle which can be described around the cross-section and the radius (rb) of that which can be inscribed in it.
Patent FI-922824-A0 (FI)
Inventor: RAMAGE PAUL IAN NICHOLAS
IPC: C07K1/36
Filed: 1992-06-17
Abstract: Following are described. (A) purified prepn. of an anti-CDw52 antibody which exhibits on size exclusion chromatography a single peak under non-reducing conditions and 2 major peaks under reducing conditions; esp. the prepn. exhibits on conventional SDS polyacrylamide gel electrophoresis, one main band using a non-reduced sample and two main bands using a reduced sample; (B) purified prepn. of an anti-CDw52 antibody having a specific activity greater than 0.8 KU/mg; (C) purified prepn. of an anti-CDw52 antibody, free from host cell contaminants and/or aggregates; (D) purifying an anti-CDw52 antibody comprising (a) applying an aqs. soln. of the antibody to a Protein A column so as to absorb the antibody and eluting the antibody with an acid soln., (b) applying the acidic eluate to an ion-exchange column of charged particles to absorb the antibody and then eluting the antibody with an aqs. soln. of counter-charged ions and (c) applying the aqs. eluate to a size exclusion column of porous particles to retain non-antibody mols. in the porous particles and to obtain the desired antibody in selected fractions produced from the column. Pref. the Protein A column is Protein A Sepharose and the antibody is eluted with citric acid.
Patent FI-925723-A0 (FI)
Inventor: MAYESTRE FRANCOIS
IPC: G01N30/02
Filed: 1992-12-16
Abstract: An analytic separation arrangement (1) comprises a system of tubes (2 - 9) including a separation zone (6), preferably a separation column, which tubes upstream the separation zone (6) are connected with reservoirs (10, 11) for an carrier (E) and a chemical sample (S) to be seperated and analyzed, and downstream the separation zone (6) are connected with a waste container (12) for the carrier containing the sample (W) and also are connected with transporting means (13, 14)for the carrier and the sample. The tube system is associated with an optical detector (15) for monitoring changes in the absorption, in the fluorescence or in the optical activity of the carrier (E) when it is transported through the tube system and past the optical detector, which is arranged in the path of the carrier behind the separation zone (6) but in front of the waste container (12). Between the separation zone (6) and the optical detector (15) there is arranged in the path of the carrier (E) a refractive index equalizing unit (16). According to the invention prior to being transported past the optical detector (15) the carrier (E), which is comming from the separation zone (6), is directed through the refractive index equalizing unit (16), where its refractive index is preferably constantly monitored and where upon detection of changes of the refractive index of the carrier the deviation is compensated by adding to the carrier a compensating agent. <IMAGE>
Patent FI-935197-A0 (FI)
Inventor: KNIEWSKE REINHARD
IPC: C08B11/12
Filed: 1993-11-23
Abstract: The present invention relates to carboxymethylcellulose (CMC) having a lower degree of substitution and to its use in textile printing.
Patent FI-950230-A0 (FI)
Inventor: BURKE PHILIP JOHN
IPC: A61P35/00
Filed: 1995-01-19
Abstract: Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT). The prodrugs are substrates for carboxypeptidase G2 (CPG2) and yield more active cytotoxic drugs than known products of CPG2 catalysed reactions.
Patent FI-954615-A0 (FI)
Inventor: CASARA PATRICK
IPC: A61P31/12
Filed: 1995-09-28
Abstract: Novel unsaturated phosphonate derivatives of certain purines or pyrimidines useful as antiviral agents, to methods and intermediates useful for their preparation and to their end-use application as antiviral agents effective against DNA viruses, retroviruses and viruses involved in tumor formation.
Patent FI-971026-A0 (FI)
Inventor: MOWBRAY CHARLES ERIC
IPC: A61P25/20
Filed: 1997-03-12
Abstract: PCT No. PCT/EP95/03483 Sec. 371 Date Mar. 12, 1997 Sec. 102(e) Date Mar. 12, 1997 PCT Filed Sep. 1, 1995 PCT Pub. No. WO96/08485 PCT Pub. Date Mar. 21, 1996Compounds of formula (I):    <IMAGE>  (I)  and their pharmaceutically acceptable salts, wherein R1 and R2 are each independently Cl, Br, CH3, CH2CH3 or CF3; R3 is H, CH3 or CH2CH3; and X is a 5-membered heterocyclic group containing up to four nitrogen atoms, attached via a nitrogen atom, the said group being optionally substituted by C1-C6 alkyl or (CH2)nNR4R5, wherein n is an integer from 1 to 5 and R4 and R5 are each independently H, C1-C6 alkyl, C3-C6 cycloalkyl or C1-C4 alkyl substituted by phenyl or pyridyl, or R4 and R5 are linked to form, together with the nitrogen atom to which attached, a pyrrolidine, piperidine, piperazine, N-(C1-C4 alkyl) piperazine, morpholine or azepine group, or, when X is triazolyl, said group may optionally be benzofused, are NMDA antagonists of value in the treatment of acute neurodegenerative disorders, e.g. arising from stroke or traumatic head injury and in chronic neurological disorders, e.g. senile dementia and Alzheimer's disease.
Patent FI-973025-A0 (FI)
Inventor: WORTHEN W G
IPC: A61B/
Filed: 1997-07-16
Abstract: The sampling device includes a cylindrical barrel having an open circular front end and an open circular rear end terminating in a radially extending irregularly shaped finger grip flange. A plunger assembly slidably received within the barrel includes a circular brush and surrounding circular sponge for collecting cervical tissue and mucous. The brush and sponge collection assembly is detachably secured to the plunger shaft by a quick release connection. In use, the barrel is inserted by a female into her vagina with the sponge and brush disposed in a retracted condition within the barrel. After insertion, the plunger is moved to an extended condition and rotated to collect tissue and mucous samples on the brush and sponge. After the samples have been collected, the sponge and brush are detached from the plunger shaft and mailed in a sealed container to a laboratory for analysis.
Patent IL-75077-A0 (IL)
Title: N,3-disubstituted 2-oxindole-1-carboxamides and pharmaceutical compositions containing them
IPC: C07D209/70
Filed: 1985-05-02
Abstract: 2-Oxindole-1-carboxamide intermediates of the formula: <CHEM>  wherein X and Y are each hydrogen, 5-fluoro, 6-fluoro, 5-chloro, 6-chloro, 5-trifluoromethyl or 6-trifluoromethyl, provided that X and Y are not both hydrogen; and R is alkyl having from 1 to 6 carbons, cycloalkyl having from 3 to 7 carbons, benzyl, furyl, thienyl, pyridyl or a group of the formula <CHEM> wherein R<1> and R<2> are each hydrogen, fluoro, chloro, alkyl having 1 to 4 carbons, alkoxy having 1 to 4 carbons or trifluoromethyl.
Patent IL-84515-A0 (IL)
Title: Rebeccamycin analogs,their production and pharmaceutical compositions containing them
IPC: C07H19/044
Filed: 1987-11-18
Abstract: There are disclosed analogs of the antitumor agent, rebeccamycin, having the formula <CHEM>  wherein:  n is an integer from 1 to 6; A<6> and A<1><3> are selected from H and -(CH2)nNR<1>R<2> and at least one of A<6> and A<1><3> is -(CH2)n-NR<1>R<2>; R<1> and R<2>, independently, are selected from hydrogen, unsubstituted and substituted C1-C6 alkyl, aralkyl having 1 to 3 carbons in the alkyl moiety and unsubstituted phenyl or phenyl substituted with 1 to 3 alkyl, alkoxy, hydroxy, halo, carboxyl, alkoxycarbonyl, and amino and mono- and di-lower-alkylamino groups in the aryl moiety, and aryl selected from unsubstituted phenyl and phenyl substituted with 1 to 3 alkyl, alkoxy, hydroxy, halo, amino, mono- and dialkylamino, nitro, carboxyl, alkoxycarbonyl, and cyano groups provided that both R<1> and R<2> are not each aryl and, when taken together, R<1> and R<2> may be selected from -(CH2)4- and (CH2)2-R<3>-(CH2)2- to form a 5- or 6-membered ring together with the N-atom wherein R<3> is selected from CH2, NH, O and S; X is selected from H, F, Cl, Br, C1-C3 alkyl, OH, carboxyl, alkoxycarbonyl and alkoxy wherein the alkyl moiety is C1-C3 alkyl, benzyloxy, amino, and mono- and dialkylamino; and R<4> is selected from H and CH3; and pharmaceutically acceptable acid addition and base salts thereof. The compounds possess antineoplastic properties against mammalian, particularly experimental animal, tumor systems. The compounds of the invention are aminoalkylated derivatives of rebeccamycin produced by first reacting rebeccamycin with a strong base to obtain a reactive intermediate and then reacting the reactive intermediate with an aminoalkyl compound.
Patent IL-87409-A0 (IL)
Title: Expression plasmids containing the deo promoter,and bacterial hosts containing the plasmids
IPC: C12P21/00
Filed: 1988-08-11
Abstract: Plasmids are provided which upon introduction into a suitable Escherichia coli host render the host capable of effecting expression of DNA encoding a desired naturally-occurring polypeptide or polypeptide analog thereof under the control of the deo P1-P2 promoter. Further plasmids are also provided which thermoinducibly direct expression of eucaryotic genes under the control of a  lambda PL promoter and a thermolabile repressor protein present on the same plasmid under the control of a deo P1 promoter. These plasmids have been inserted into various hosts, some of which contain DNA encoding the repressor protein. Such plasmids may be used to produce polypeptides such as human copper/zinc superoxide dismutase, hMnSOD-hGPX fusion polypeptides, human manganese superoxide dismutase, human growth hormone, bovine growth, porcine growth, human growth hormone-apolipoprotein E fused polypeptides, apolipoprotein E and various fibronectin domains.
Patent IL-96659-A0 (IL)
Title: 2-substituted 4-(3-alkyl-5-tert.-butyl-4-hydroxyphenyl)-thiazoles,processes for their preparation,pharmaceuticals containing them and their use
IPC: C07D417/12
Filed: 1990-12-13
Abstract: Novel substituted thiazoles of the formula I   <IMAGE> (I)  in which R1 is a saturated or unsaturated, straight-chain or branched C1-C5-alkyl group, R2 is a hydrogen atom or an alkyl radical having 1 to 3 carbon atoms, A is an intermediate chain of the formula -(CH2)n-Y-CR3R4-; -CH=CR3-(CH2)m- or -CH=N-O-(CH2)n-  where Y is a single bond, an oxygen or sulfur atom or a carbonyl group, R3 and R4 are identical or different and are a hydrogen atom or an alkyl radical having up to two carbon atoms, m is a number from 0 to 3 and n is a number from 1 to 4, and Z is a tetrazole or CN group, or a radical of the formula  <IMAGE>  X is a hydroxyl group or a radical of the formula R5O- or R6R7N-, where R5 is a straight-chain or branched C1-C4-alkyl radical which is optionally substituted by hydroxyl, C1-C3-alkoxy or C1-C3-alkylamino, R6 and R7 are identical or different and are a hydrogen atom, a straight-chain or branched C1-C6-alkyl radicall or, for the case in which R6 is a hydrogen atom or a C1-C4-alkyl radical, R7 is a hydroxyl, a C1-C3-alkoxy or a tetrazol-5-yl group or X, together with the structural element -A-(C=O)-, is a radical of the formula II   <IMAGE> (II)   where R8 is a hydrogen atom, a C1-C3-alkyl radical or a C1-C3-alkoxy radical, and physiologically tolerable salts of such compounds of the formula I in which X is a hydroxyl or hydroxyamino group, are prepared by various processes. They are preferably suitable for the treatment and prophylaxis of inflammatory diseases - in particular inflammatory rheumatic diseases.
Patent IL-97380-A0 (IL)
Title: Networked satellite and terrestrial cellular radiotelephone systems
IPC: H04W72/04
Filed: 1991-02-28
Abstract: There is provided a mechanism for networking satellite and terrestrial networks. It comprises: maintaining subscriber-received power levels of terrestrial network transmissions about one order of magnitude above co-channel satellite transmissions to overcome interference and maintaining subscriber transmissions to terrestrial networks at power levels about one order of magnitude of the below co-channel transmissions to satellite networks to avoid causing interference at the satellite. Such power level maintenance is provided by the network in communication with such subscriber. Moreover, a non-orbiting ("grounded") satellite cooperates as a switching node of both the satellite network and a terrestrial network to relay information between a terrestrial subscriber and the satellite radiotelephone network over a terrestrial network. The terrestrial network and the satellite network may communicate via either the inter-satellite spectrum or the terrestrial-to-satellite spectrum. <IMAGE>
Patent IL-98175-A0 (IL)
Title: Pharmaceutical compositions containing certain tetrahydropyridine derivatives for the treatment of cerebral and neuronal diseases
IPC: G01N33/50
Filed: 1991-05-17
Abstract: The invention relates to a method of evaluation of substances which are active at neuronal level, which consists in producing neuronal lesions in experimental animals by injecting an effective amount of vincristine into their medium septum, and in then evaluating the activity of the aforementioned substances in morphological and/or biochemical tests.
Patent AU-PQ726600-A0 (AU)
Title: System and method for continuous monitoring of the structural integrity of a component or structure
IPC: G01N3/02
Filed: 2000-05-03
Abstract: A system 10 for continuously monitoring the integrity of a structure 14 includes a sensor pad 16 having a surface 18. The surface 18 is provided with a set of first channels 22 and interspersed second channels 24. Surface 18 is sealed onto the surface 12 of structure 14 so that the channels 22, 24 together with surface 12 form respective sets of first and second cavities 26 and 28. The first cavities 26 are placed in fluid communication with a vacuum source 101 via a third channel 30. The second cavities 28 are vented to the atmosphere via a fourth channel 34, through hole 35, and conduit 36. A high impedance 102 is placed in series between the vacuum source 101 and the first cavities 26. A differential pressure transducer 103 is connected across the high impedance 102 and monitors for change in vacuum condition between the vacuum source 101 and the vacuum in the cavities 26. If a fault 40 were to develop in structure 14 opening onto surface 12 and propagate to form a fluid communication path between one of the cavities 26 and adjacent cavity 28 there will be a change in the vacuum condition of the cavity 26 which will be detected by the transducer 103.
Patent FI-20000043-A0 (FI)
Inventor: VIRTANEN ANU
IPC: H04W36/08
Filed: 2000-01-10
Abstract: A method ( 600 ) for preparing an interfrequency handover of a certain communication connection from a first frequency to a second frequency features periodically intermitting ( 603 ) the transmission/receipt of data on the first frequency for certain transmission gaps. The number of transmission gaps is at least one during each transmission period and a certain sequence of transmission periods ( 420, 520 ) is used. Measurements are performed ( 607 ) on the second frequency during the transmission gaps on the first frequency. In the step of intermitting the transmission/receipt of data the transmission/receipt of data is intermitted within at least on transmission period for a certain transmission gap ( 311, 411 ) having a first duration and for a certain second transmission gap ( 312, 412 ) having a second duration. The second duration is different from the first duration. A mobile station ( 700 ), a network element ( 710 ) and a network control element ( 720 ) are also presented.
Patent FI-20031256-A0 (FI)
Inventor: ROMO PASI
IPC: B65B27/10
Filed: 2003-09-04
Abstract: The invention relates to a method and a device for processing wood. Wood is fed with a feed conveyor (4) into a feed chamber (3) and then cut. The cut wood is transferred away from the feed chamber (3) by vertically moving a bottom (17) in the feed chamber. Above the feed chamber (3) is provided an i n-termediate chamber (7) comprising at least one conveyor (19) for receiving and transferring the wood forward to a compression chamber (8). <IMAGE> <IMAGE>
Patent FI-20065536-A0 (FI)
Inventor: HUKKANEN PENTTI
Filed: 2006-08-30
Abstract: The present invention relates to a locking device used in a working machine (1) that is composed of at least two frame parts (4, 5) and moves in a terrain. The locking device is disposed in a rotating joint that interconnects the frame parts (4, 5) and enables the rotation of the frame parts relative to one another with respect to the longitudinal axis (7) of the working machine. Such a device comprises gripping means (8, 9) that are controllable against each other into a mechanical contact and that partly or entirely prevent a rotational movement between the frame parts (4, 5). These gripping means (8, 9) comprise a passive means (8) arranged rigid relative to its receiving frame part. The means thus extends at least partly around the axial direction of the rotating joint. The gripping means further comprise an active means (9) arranged to be controllable against the first passive member (8) with at least one actuator.
Patent IL-110275-A0 (IL)
Title: Substituted 2-phenylpyridines, compositions containing them and the preparation of these compositions
IPC: C07D213/61
Filed: 1994-07-11
Abstract: PCT No. PCT/EP94/02264 Sec. 371 Date Jan. 11, 1996 Sec. 102(e) Date Jan. 11, 1996 PCT Filed Jul. 11, 1994 PCT Pub. No. WO95/02590 PCT Pub. Date Jan. 26, 1995A substituted 2-phenylpyridine of the formula I where Ar is and the N-oxides of I and the agriculturally utilizable salts of I where these exist. Use: herbicides; desiccation/defoliation of plants.
Patent IL-117850-A0 (IL)
Title: Altered polypeptides with increased half-life
IPC: C07K4/12
Filed: 1996-04-08
Abstract: Polypeptides that are cleared from the kidney and do not contain in their original form a Fc region of an IgG are altered so as to comprise a salvage receptor binding epitope of an Fc region of an IgG and thereby have increased circulatory half-life.
Patent IL-118360-A0 (IL)
Title: Process for the preparation of a halosubstituted aromatic acid
IPC: C07C227/06
Filed: 1996-05-22
Abstract: The present invention refers to a process for the preparation of 5-amino-2,4,6-triiodo-1,3-benzenedicarboxylic acid, comprising the following steps: a) catalytic hydrogenation of 5-nitro-1,3-benzenedicarboxylic acid in neutral or basic environment, which gives an aqueous solution of 5-amino-1,3-benzenedicarboxylic acid sodium salt; b) direct iodination of the 5-amino-1,3-benzenedicarboxylic acid sodium salt solution deriving from step a), without further purification, with a solution of ICl in HCl, being the 5-amino-1,3-benzenedicarboxylic acid sodium salt solution previously added with HCl and H2SO4.
Patent IL-127645-A0 (IL)
Title: Method and apparatus for data processing
IPC: G06F1/00
Filed: 1997-06-18
Abstract: The invention relates to a method and an apparatus for processing data that is to be protected. The data is stored as encrypted data element values (DV) in records (P) in a first database (O-DB), each data element value being linked to a corresponding data element type (DT). In a second database (IAM-DB), a data element protection catalogue (DC) is stored, which for each individual data element type (DT) contains one or more protection attributes stating processing rules for data element values (DV), which in the first database (O-DB) are linked to the individual data element type (DT). In each user-initiated measure which aims at processing a given data element value (DV) in the first database (O-DB), a compelling calling is initially sent to the data element protection catalogue for collecting the protection attribute/attributes associated with the corresponding data element types. The user's processing of the given data element value is compellingly controlled in conformity with the collected protection attribute/attributes.